ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,722.86
      1.86%
      US Tech 100
      19,382.86
      2.79%
      Dow Jones
      42,091.29
      1.42%
      Brent Oil
      74.15
      2.45%
      Bitcoin
      63,555.97
      3.06%
      Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Coeptis Therapeutics Holdings Inc (COEP)

      7. Coeptis Therapeutics Holdings Inc (COEP) News

      COEP

      Coeptis Therapeutics (COEP)

      Coeptis Therapeutics Holdings Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:COEP
      DateTimeSourceHeadlineSymbolCompany
      09/19/20247:07AMPR Newswire (US)Coeptis Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued ListingNASDAQ:COEPCoeptis Therapeutics Holdings Inc
      09/05/20248:07AMPR Newswire (US)Coeptis Therapeutics Chief Executive Officer, Dave Mehalick, Updates and Outlines Strategic Vision in Letter to ShareholdersNASDAQ:COEPCoeptis Therapeutics Holdings Inc
      08/16/20244:02PMEdgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:COEPCoeptis Therapeutics Holdings Inc
      08/16/20244:01PMEdgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:COEPCoeptis Therapeutics Holdings Inc
      08/14/20245:26PMEdgar (US Regulatory)Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSBNASDAQ:COEPCoeptis Therapeutics Holdings Inc
      08/14/20245:25PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:COEPCoeptis Therapeutics Holdings Inc
      07/31/20245:00PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:COEPCoeptis Therapeutics Holdings Inc
      06/20/20248:47AMPR Newswire (US)Coeptis Therapeutics Closes on $4.3 Million of Series A Preferred OfferingNASDAQ:COEPCoeptis Therapeutics Holdings Inc
      05/30/20248:47AMPR Newswire (US)Coeptis Therapeutics' Dr. Colleen Delaney to Present at Allogeneic Cell Therapies Summit 6th Annual MeetingNASDAQ:COEPCoeptis Therapeutics Holdings Inc
      05/08/20248:47AMPR Newswire (US)Coeptis Therapeutics to Present its Universal Allogeneic SNAP-CAR NK Cell Therapy at the ISCT 2024NASDAQ:COEPCoeptis Therapeutics Holdings Inc
      05/02/20248:47AMPR Newswire (US)Coeptis Therapeutics Announces Poster Data Presentation at American Society of Gene & Cell Therapy (ASGCT) 27th Annual MeetingNASDAQ:COEPCoeptis Therapeutics Holdings Inc
      04/02/20248:47AMPR Newswire (US)Coeptis Therapeutics Congratulates Alexander Deiters, Professor at the University of Pittsburgh, on Receiving the 2024 Chancellor's Distinguished Research AwardNASDAQ:COEPCoeptis Therapeutics Holdings Inc
      02/26/20249:00AMPR Newswire (US)Coeptis Therapeutics Adds Autoimmune Indications to Exclusive License Agreement with University of Pittsburgh for SNAP-CAR T and SNAP-CAR NKNASDAQ:COEPCoeptis Therapeutics Holdings Inc
      02/07/20247:30AMPR Newswire (US)Coeptis Therapeutics to Pursue Phase 2 Program Using Proprietary First-in-Class Allogeneic NK Cell Therapy for the Treatment of Viral InfectionsNASDAQ:COEPCoeptis Therapeutics Holdings Inc
      01/04/20247:30AMPR Newswire (US)Coeptis Therapeutics President and CEO Issues Letter to Shareholders Highlighting 2023 Accomplishments and Outlook for 2024NASDAQ:COEPCoeptis Therapeutics Holdings Inc
      10/31/20239:01AMPR Newswire (US)Coeptis Therapeutics Announces Research Demonstrating the Potential of SNAP-CAR T-cells to Reduce Tumor Burden and Growth in HER2 and CD20 Expressing Cancers Will be Presented at SITC 2023NASDAQ:COEPCoeptis Therapeutics Holdings Inc
      10/24/20238:30AMPR Newswire (US)Coeptis Therapeutics Announces $2 Million Private PlacementNASDAQ:COEPCoeptis Therapeutics Holdings Inc
      10/11/20237:30AMPR Newswire (US)Coeptis Therapeutics Expands License Agreement with University of Pittsburgh to Include SNAP-CAR NK Cell TechnologyNASDAQ:COEPCoeptis Therapeutics Holdings Inc
      10/09/20239:15AMPR Newswire (US)Coeptis Therapeutics to Participate in Panel at the BioFlorida Conference Discussing Emerging Cell and Gene TherapiesNASDAQ:COEPCoeptis Therapeutics Holdings Inc
      10/04/20237:30AMPR Newswire (US)Coeptis Therapeutics Announces Research Involving SNAP-CAR Accepted for Presentation at the Society for Immunotherapy of Cancer's 38th Annual MeetingNASDAQ:COEPCoeptis Therapeutics Holdings Inc
      09/27/20237:30AMPR Newswire (US)Coeptis Therapeutics to Present at the 2023 Cell & Gene Meeting on the MesaNASDAQ:COEPCoeptis Therapeutics Holdings Inc
      09/14/20237:30AMPR Newswire (US)Coeptis Therapeutics Provides Safety and Dosing Update from Phase 1 Trials Investigating DVX201 in Relapsed/Refractory AML or High Risk MDS and Hospitalized COVID-19 InfectionNASDAQ:COEPCoeptis Therapeutics Holdings Inc
      09/11/20237:30AMPR Newswire (US)Coeptis Therapeutics Announces Deverra Therapeutics Has Received Two Life Science Start-Up and Development Awards and Associated Grant from Washington's Cancer Research EndowmentNASDAQ:COEPCoeptis Therapeutics Holdings Inc
      08/30/20231:00PMPR Newswire (US)Coeptis Therapeutics Appoints Colleen Delaney, MD, as Chief Scientific and Medical OfficerNASDAQ:COEPCoeptis Therapeutics Holdings Inc
      08/17/20237:30AMPR Newswire (US)Coeptis Therapeutics Completes Exclusive License for Allogeneic Immuno-Oncology Platform and Clinical Stage Assets from Deverra TherapeuticsNASDAQ:COEPCoeptis Therapeutics Holdings Inc
      08/01/20238:00AMPR Newswire (US)Coeptis Therapeutics Files FDA 513(g) Submission for CD38 In Vitro Companion DiagnosticNASDAQ:COEPCoeptis Therapeutics Holdings Inc
      06/16/20234:00PMPR Newswire (US)Coeptis Therapeutics Holdings, Inc. Announces Closing of $3.5 Million Underwritten OfferingNASDAQ:COEPCoeptis Therapeutics Holdings Inc
      06/14/20239:28AMPR Newswire (US)Coeptis Therapeutics Holdings, Inc. Announces Pricing of $3.5 Million Underwritten OfferingNASDAQ:COEPCoeptis Therapeutics Holdings Inc
      06/09/20237:00AMPR Newswire (US)Coeptis Therapeutics Receives Approval to Transfer to The Nasdaq Capital MarketNASDAQ:COEPCoeptis Therapeutics Holdings Inc
      05/17/20238:30AMPR Newswire (US)Coeptis Therapeutics Appoints Brian Cogley as Chief Financial OfficerNASDAQ:COEPCoeptis Therapeutics Holdings Inc
       Showing the most relevant articles for your search:NASDAQ:COEP